Earnings 25 Feb 2026: Fresenius SE (FRE.DE XETRA) impact on EUR 52.08 stock
FRE.DE stock trades at EUR 52.08 ahead of Fresenius SE & Co. KGaA’s earnings due 25 Feb 2026. The company reports after the close and the market is watching Fresenius Medical Care margins and Helios hospital volumes. Intraday volume sits at 591,547 versus an average of 671,873, keeping price action tight between a day low of EUR 51.72 and a day high of EUR 52.96. Investors should weigh segment profit momentum, valuation at PE 25.23, and cash flow metrics before the Q4 print.
Earnings preview: FRE.DE stock and market context
Fresenius reports Q4 results on 25 Feb 2026 at 16:30 UTC; market focus is on operating profit and segment guidance. Expectations center on margin recovery in Fresenius Medical Care and steady IV drug demand at Fresenius Kabi. The Healthcare sector in Germany is modest this year, up 0.26% YTD, so Fresenius will be judged versus peers and sector trends.
Recent segment news and what to watch
Fresenius Medical Care posted a strong operating profit update that lifted sentiment for the dialysis business. Investors should watch revenue growth, dialysis service volumes, and one-off items that affected Q4 margins. For sources on recent segment performance see Reuters and MarketBeat for the Medical Care Q4 update source and the Q4 filing summary source.
Key financials and valuation snapshot
Fresenius trades at PE 25.23 with EPS EUR 2.05 and market cap about EUR 29.13 billion. Balance-sheet metrics show debt/equity 0.73 and interest coverage 6.34, while free cash flow yield is roughly 4.15%. Price sits above the 50-day average (EUR 49.17) and 200-day average (EUR 46.41). These ratios frame a mixed valuation: reasonable price-to-sales (1.30) but elevated net debt to EBITDA (3.34).
Meyka AI grade and model forecast for FRE.DE stock
Meyka AI rates FRE.DE with a score out of 100: 69.96 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term lift, with monthly EUR 55.47, quarterly EUR 55.87, and yearly EUR 61.31. Versus the current price EUR 52.08, implied upside is 6.51% (monthly), 7.28% (quarterly), and 17.74% (yearly). Forecasts are model-based projections and not guarantees.
Technical setup and trading cues
Momentum indicators show moderate strength: RSI 62.99, MACD histogram 0.22, and ADX 25.60 suggesting a trend. Near-term resistance sits at the year high EUR 52.96 and support around the 50-day average EUR 49.17. Average true range is EUR 0.97, so traders can size risk with stops near EUR 51.00 on intraday setups. Volume is slightly below average, keeping moves contained ahead of earnings.
Risks and upcoming catalysts for FRE.DE stock
Primary risks include weaker dialysis pricing, slower hospital admissions, and one-off restructuring charges. Net debt to EBITDA of 3.34 increases sensitivity to cash flow shocks. Key catalysts are the Q4 earnings release, management guidance, and any commentary on capital allocation or dividend policy. Watch for revisions to FY margin guidance and any segment-level surprises that could swing the stock.
Final Thoughts
Fresenius (FRE.DE stock) is trading in a narrow band at EUR 52.08 as markets position ahead of the 25 Feb 2026 Q4 report. The balance of facts favors a cautious stance: operating strength in Fresenius Medical Care is a positive, but leverage and mixed cash flow trends limit upside. Meyka AI’s model shows short-term upside to EUR 55.47 (≈6.51%) and a one-year projection of EUR 61.31 (≈17.74%). For active traders, key levels are EUR 52.96 (resistance) and EUR 49.17 (50-day support). For longer-term investors, valuation at PE 25.23, dividend yield near 1.93%, and net debt metrics argue for waiting on clearer guidance. Meyka AI provides this AI-powered market analysis to help frame outcomes; forecasts are model-based projections and not guarantees.
FAQs
When does Fresenius report earnings and how could it affect FRE.DE stock?
Fresenius reports Q4 on 25 Feb 2026 at 16:30 UTC. Results on margins, dialysis volumes, and guidance can move FRE.DE stock intraday, with upside if Medical Care margins exceed expectations and downside if guidance weakens.
What are the key valuation metrics to watch for Fresenius?
Watch PE 25.23, free cash flow yield 4.15%, debt/equity 0.73, and price-to-sales 1.30. These show fair valuation but elevated leverage versus cash flow.
What price targets does Meyka AI give for FRE.DE stock?
Meyka AI’s forecast model projects EUR 55.47 monthly and EUR 61.31 yearly. These imply roughly 6.51% and 17.74% upside respectively versus the current EUR 52.08.
What are the main risks investors should consider?
Main risks include dialysis pricing pressure, weaker hospital admissions, and the company’s net debt to EBITDA of 3.34. Any negative surprise on margins or cash flow could pressure FRE.DE stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.